Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
polyethylene glycol 35
- Development stage
- Unknown
- Lead developer
- IGL Group
- Modality
- Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Administration
- Intravenous, Parenteral
01
Overview
Polyethylene glycol 35 (PEG35) is a water-soluble, non-immunogenic, and non-toxic polymer of ethylene glycol with an average molecular weight of 35 kDa. It is widely utilized as an oncotic and cytoprotective agent in organ preservation solutions, such as Institut Georges Lopez-1 (IGL-1), IGL-2, and IGL-2M, to prevent cell swelling, maintain membrane integrity, and reduce ischemia-reperfusion injury during static cold storage and machine perfusion of transplant grafts (including liver, kidney, and lung). Beyond its biophysical role as an osmotic/oncotic agent, PEG35 activates several cytoprotective and cell-survival pathways, including AMP-activated protein kinase (AMPK), endothelial nitric oxide synthase (eNOS) for nitric oxide production, and the Nrf2/HO-1 antioxidant response. Additionally, PEG35 is under preclinical investigation as an intravenous therapeutic agent to ameliorate inflammation and cell death in acute necrotizing pancreatitis and associated lung injury.
- Other names
- PEG 35PEG35PEG-35PEG 35 kDaPEG35 kDaPEG-35 kDaPEG 35000PEG35000PEG-35000polyethylene glycol 35 kDapolyethylene glycol 35,000polyethylene glycol 35000
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)ALDH2 (Mitochondrial Aldehyde Dehydrogenase)NOS3 (eNOS)HMOX1 (Heme oxygenase 1)NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)
Beyond the preview
Go deeper on polyethylene glycol 35.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on polyethylene glycol 35.